Debiopharm International SA

ViewsML CEO Details AI-Driven Virtual Multiplexing Strategy Following $4.9M Seed Round

Following an oversubscribed $4.9 million seed round, supported by Debiopharm alongside lead investor Wittington Ventures, Mayo Clinic, and Continuum Health Ventures, our portfolio company ViewsML is deploying the new capital to expand its team and accelerate the commercialization of its virtual…

Nucleai Joins CellCarta’s Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development

In a major step forward for drug development, Nucleai has joined CellCarta’s newly launched Consortium, a curated ecosystem of leading digital pathology, artificial intelligence, and precision diagnostics innovators. By combining CellCarta’s pathologist-directed workflows, whole-slide scanning,…

VeriSIM Life Formalizes Research Collaboration with FDA/NCTR, Advancing the Next Generation of Mechanistic AI for Drug Development

VeriSIM Life has signed a Material Transfer Agreement (MTA) with the FDA’s National Center for Toxicological Research (FDA/NCTR), establishing an official framework to leverage its hybrid AI platform, BIOiSIM, to help narrow the persistent translational gap between preclinical testing and human…

ViewsML Secures Funding to Accelerate Commercialization of AI-Driven Virtual Biomarker Staining Platform

ViewsML has successfully closed an oversubscribed $4.9M seed round, marking a major milestone in their mission to transition tissue analysis from a manual laboratory task into a high-performance software solution. As a repeat investor, we are proud to continue our partnership with ViewsML. Their…

Iktos and Chemspeed Partner to Bring AI-Orchestrated Laboratory Automation to Pharmaceutical R&D

Iktos and Chemspeed Technologies (a Bruker company) recently announced a collaboration to bridge the gap between AI-driven molecule design and physical chemical synthesis. As a strategic investor in Iktos, we are pleased to see their orchestration technology integrated with Chemspeed’s world-class…

BC Platforms partners with OmicsBank to expand access to large-scale real-world and multi-omics data from India and the UAE

BC Platforms has announced a strategic partnership with OmicsBank to enable access to longitudinal and multi-modal real-world clinical and multi-omics datasets from emerging markets. The collaboration adds approximately 12 million patient lives from India and 500,000 from the UAE to BC Platforms’…